![](/img/cover-not-exists.png)
EV-103 Study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer
Hoimes, C.J., Petrylak, D., Flaig, T., Carret, A.-S., Melhem-Bertrandt, A., Gartner, E., Rosenberg, J.Volume:
17
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/S1569-9056(18)31639-7
Date:
March, 2018
File:
PDF, 83 KB
english, 2018